Promising results from comparative study with Episealer® accepted for presentation at German orthopaedic congress
Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Comparable clinical outcomes after autologous matrix-induced chondrogenesis versus implantation of single patient-specific metal implants in focal femoral chondral lesions of the middle-aged patient” has been accepted for a podium presentation at the German Congress of Orthopaedics and Traumatology, DKOU 2022, which will take place in Berlin, Germany, on October 25-28, 2022. The presentation will be held by Priv.-Doz. Dr. med. Clemens Kösters, Maria-Josef-Hospital Greven, Germany.
“We have come to a stage where our Episealer® Knee implant is not only used for patients who are too old for biological treatment alternatives, but also as a treatment for patients where biological treatment alternatives used to be the preferred option. We know from previous studies that our results are predictable, and we look forward to seeing the final results from this ongoing comparative study where our technology is compared with one of the most accepted biological treatment alternatives”, says Pål Ryfors, CEO Episurf Medical.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"></p>
[HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif"><strong>Promising results from comparative study with Episealer® accepted for presentation at German orthopaedic congress</strong></span></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Comparable clinical outcomes after autologous matrix-induced chondrogenesis versus implantation of single patient-specific metal implants in focal femoral chondral lesions of the middle-aged patient” has been accepted for a podium presentation at the German Congress of Orthopaedics and Traumatology, DKOU 2022, which will take place in Berlin, Germany, on October 25-28, 2022. The presentation will be held by Priv.-Doz. Dr. med. Clemens Kösters, Maria-Josef-Hospital Greven, Germany.
“We have come to a stage where our Episealer® Knee implant is not only used for patients who are too old for biological treatment alternatives, but also as a treatment for patients where biological treatment alternatives used to be the preferred option. We know from previous studies that our results are predictable, and we look forward to seeing the final results from this ongoing comparative study where our technology is compared with one of the most accepted biological treatment alternatives”, says Pål Ryfors, CEO Episurf Medical.
[HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><span style="color:#0e101a">Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “<em>Comparable clinical outcomes after autologous matrix-induced chondrogenesis versus implantation of single patient-specific metal implants in focal femoral chondral lesions of the middle-aged patient</em>” has been accepted for a podium presentation at the German Congress of Orthopaedics and Traumatology, DKOU 2022, which will take place in Berlin, Germany, on October 25-28, 2022. The presentation will be held by Priv.-Doz. Dr. med. Clemens Kösters, Maria-Josef-Hospital Greven, Germany.</span></span></span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><em><span style="color:#0e101a">“We have come to a stage where our Episealer</span></em>®<em> </em><em><span style="color:#0e101a"> Knee implant is not only used for patients who are too old for biological treatment alternatives, but also as a treatment for patients where biological treatment alternatives used to be the preferred option. We know from previous studies that our results are predictable, and we look forward to seeing the final results from this ongoing comparative study where our technology is compared with one of the most accepted biological treatment alternatives”,</span></em><span style="color:#0e101a"> says Pål Ryfors, CEO Episurf Medical.</span></span></span></span></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 14326
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Pål Ryfors
[3] => Episealer
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3586835/1593812.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Promising results from comparative study with Episealer® accepted for presentation at German orthopaedic congress
[Description:protected] => Promising results from comparative study with Episealer® accepted for presentation at German orthopaedic congress
[CreateDate:protected] => 2022-06-16T11:13:33.953Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 4291629
[EncryptedId:protected] => 587035EAFEA44F35
[IsRegulatory:protected] =>
[PublishDate:protected] => 2022-06-16T11:13:19Z
[LastChangeDate:protected] => 2022-06-16T11:13:33.923Z
[Title:protected] => Promising results from comparative study with Episealer® accepted for presentation at German orthopaedic congress
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/promising-results-from-comparative-study-with-episealer--accepted-for-presentation-at-german-orthopa,c3586835
[LanguageVersions:protected] => Array
(
[0] => CisionBlockPro\Cision\LanguageVersion Object
(
[Code:protected] => sv
[ReleaseId:protected] => 4291631
)
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)